Is bictegravir (BIC)/tenofovir alafenamide (TAF)/emtricitabine (FTC) once daily for 28 days recommended for post-exposure prophylaxis (PEP) after unknown exposure to HIV due to unprotected sex?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Bictegravir/Tenofovir Alafenamide/Emtricitabine (BIC/TAF/FTC) for HIV Post-Exposure Prophylaxis

Yes, BIC/TAF/FTC once daily for 28 days is recommended for post-exposure prophylaxis (PEP) after unknown exposure to HIV through unprotected sex. 1

Recommended PEP Regimen

  • BIC/TAF/FTC is a CDC-recommended preferred regimen for adults and adolescents requiring PEP, administered as a single tablet once daily for 28 days 1
  • PEP should be initiated as soon as possible after exposure, preferably within 1-2 hours, but can be started up to 72 hours post-exposure 1, 2
  • The complete 28-day course is essential for maximum effectiveness 1, 2

Evidence Supporting BIC/TAF/FTC for PEP

  • Clinical studies have demonstrated high completion rates (90-96%) with BIC/TAF/FTC PEP regimens 3
  • BIC/TAF/FTC has shown significantly higher completion rates compared to earlier PEP regimens, including those containing other integrase strand transfer inhibitors 3
  • The most common side effects are mild and include nausea/vomiting (15.4%), fatigue (9.6%), and diarrhea (7.7%), which are less common than with historical PEP regimens 3

Timing and Duration Considerations

  • PEP must be initiated within 72 hours of exposure, with earlier initiation (ideally within 1-2 hours) providing better protection 1, 2
  • The full 28-day course is required for optimal effectiveness 1
  • HIV testing should be performed before initiating PEP and at follow-up intervals (4-6 weeks and 12 weeks after exposure) 2

Advantages of BIC/TAF/FTC

  • Available as a fixed-dose combination tablet, making it a complete single-tablet regimen 1
  • Once-daily dosing improves adherence compared to multiple-pill or multiple-daily-dose regimens 3
  • Can be taken with or without food, increasing flexibility 4
  • Demonstrates better tolerability and higher completion rates than older PEP regimens 3

Important Clinical Considerations

  • PEP can be discontinued if the source is found to be HIV-negative at any point during the course 2
  • Consider transition from PEP to PrEP after completion of the 28-day PEP course for individuals with anticipated ongoing HIV exposure risk 2
  • For unknown HIV status exposures, the decision to use PEP should be based on the risk assessment of the exposure 5

Common Pitfalls to Avoid

  • Mistaking PEP for a single-dose intervention, when it requires a full 28-day course 1
  • Delaying initiation beyond 72 hours post-exposure significantly reduces effectiveness 1
  • Failing to check for drug interactions, particularly with medications containing polyvalent cations 1
  • Not completing the full 28-day course, which is essential for maximum protection 1, 3

BIC/TAF/FTC represents a significant advancement in PEP therapy with its single-tablet, once-daily regimen that has demonstrated high completion rates and better tolerability compared to previous options 3.

References

Guideline

BIC/FTC/TAF for HIV Post-Exposure Prophylaxis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

HIV Post-Exposure Prophylaxis (PEP) Regimen Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.